Full Title
Phase 1/2 Study of PARG inhibitor ETX-19477 in Patients with Advanced Solid MalignanciesPurpose
Researchers want to find the best dose of ETX-19477 to treat cancer. The people in this study have solid tumors that keep growing even after treatment.
ETX-19477 is designed to block a protein called PARG, which plays a role in cancer cell growth. By blocking PARG, ETX-19477 may help slow or stop the growth of your cancer. ETX-19477 is taken orally (by mouth).
Contact
For more information and to see if you can join this study, please call 646-888-4226.
Protocol
24-224
Phase
Phase I/II (phases 1 and 2 combined)
Disease Status
Relapsed or Refractory
Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT06395519
ClinicalTrials.gov